C.-M. Tsai

1.4k total citations
24 papers, 1.1k citations indexed

About

C.-M. Tsai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, C.-M. Tsai has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in C.-M. Tsai's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers) and Cancer therapeutics and mechanisms (4 papers). C.-M. Tsai is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers) and Cancer therapeutics and mechanisms (4 papers). C.-M. Tsai collaborates with scholars based in Taiwan, United States and South Korea. C.-M. Tsai's co-authors include Adi F. Gazdar, Julia Cope, Emily B. Hollister, Renato A. Luna, Ann R. McMeans, James Versalovic, Robert J. Shulman, Bruno P. Chumpitazi, Jacqueline Whang‐Peng and James L. Mulshine and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

C.-M. Tsai

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.-M. Tsai Taiwan	15	629	484	447	203	140	24	1.1k
Yoichiro Kakugawa Japan	21	625 1.0×	309 0.6×	483 1.1×	50 0.2×	119 0.8×	52	1.4k
KL Goh Malaysia	11	441 0.7×	251 0.5×	198 0.4×	205 1.0×	33 0.2×	25	1.1k
Aimee L. Lucas United States	18	596 0.9×	121 0.3×	213 0.5×	32 0.2×	52 0.4×	58	1.0k
Supriya Shah United States	12	392 0.6×	227 0.5×	234 0.5×	42 0.2×	32 0.2×	20	851
Tira J. Tan Singapore	15	399 0.6×	139 0.3×	245 0.5×	39 0.2×	37 0.3×	56	752
Zeng‐Hong Wu China	15	148 0.2×	294 0.6×	431 1.0×	39 0.2×	76 0.5×	51	931
JH Kleibeuker Netherlands	6	442 0.7×	125 0.3×	108 0.2×	136 0.7×	30 0.2×	22	911
Balraj Mittal India	20	306 0.5×	185 0.4×	284 0.6×	22 0.1×	21 0.1×	43	837
H. Štern Canada	19	697 1.1×	141 0.3×	184 0.4×	34 0.2×	98 0.7×	39	1.3k
Piotr Krokowicz Poland	15	167 0.3×	46 0.1×	295 0.7×	57 0.3×	59 0.4×	49	714

Countries citing papers authored by C.-M. Tsai

Since Specialization

Citations

This map shows the geographic impact of C.-M. Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.-M. Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.-M. Tsai more than expected).

Fields of papers citing papers by C.-M. Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.-M. Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.-M. Tsai. The network helps show where C.-M. Tsai may publish in the future.

Co-authorship network of co-authors of C.-M. Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of C.-M. Tsai. A scholar is included among the top collaborators of C.-M. Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.-M. Tsai. C.-M. Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ahn, Myung‐Ju, Ji‐Youn Han, Lecia V. Sequist, et al.. (2017). OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI. Journal of Thoracic Oncology. 12(11). S1768–S1768. 24 indexed citations

Chumpitazi, Bruno P., Julia Cope, Emily B. Hollister, et al.. (2015). Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 42(4). 418–427. 277 indexed citations

Yoshioka, Hiroshige, K. Azuma, Nobuyuki Yamamoto, et al.. (2015). A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Annals of Oncology. 26(10). 2066–2072. 89 indexed citations

Wu, Yi‐Long, Lecia V. Sequist, Sarayut Lucien Geater, et al.. (2015). 446P Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). Annals of Oncology. 26. ix125–ix125. 2 indexed citations

Park, K., Myung‐Ju Ahn, Chong‐Jen Yu, et al.. (2014). Aspiration: First-Line Erlotinib (E) Until and Beyond Recist Progression (Pd) in Asian Patients (Pts) with Egfr Mutation-Positive (Mut+) Nsclc. Annals of Oncology. 25. iv426–iv426. 33 indexed citations

Wang, Shu‐Yi, C.-M. Tsai, & Chia‐Chin Lin. (2014). Relationship of Cytokines to Symptom Distress and Symptom Clusters Among Non-small-cell Lung Cancer Patients Receiving Gefitinib Treatment: A Pilot Study. Journal of Experimental & Clinical Medicine. 6(2). 50–56. 2 indexed citations

Ciuleanu, Tudor–Eliade, C.-M. Tsai, Janusz Milanowski, et al.. (2013). A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 82(2). 276–281. 26 indexed citations

Tsai, C.-M., et al.. (2013). New gas applications of backside circuit edit for voiding spontaneous damage. 2. 470–473.

Shih, Jin‐Yuan, James Chih‐Hsin Yang, Wei‐Juin Su, et al.. (2009). A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). Journal of Clinical Oncology. 27(15_suppl). 8013–8013. 21 indexed citations

10.

Chen, Yuh‐Min, James Chih‐Hsin Yang, Chong‐Jen Yu, et al.. (2003). P-544 Final results of a phase I study with navelbine (NVB) oral in combination with cisplatin (C), evaluating two different schedules in advanced non-small cell lung cancer (NSCLC) patients. Lung Cancer. 41. S229–S229. 1 indexed citations

11.

Perng, R.-P., et al.. (2002). Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Annals of Oncology. 13(1). 108–115. 49 indexed citations

12.

Perng, R.-P., et al.. (2000). A Phase II Trial of Tamoxifen, Ifosfamide, Epirubicin, and Cisplatin Combination Chemotherapy for Inoperable Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology. 23(1). 13–17. 13 indexed citations

13.

Tsai, C.-M., et al.. (2000). Restoration of Cytotoxic T Lymphocyte Function in Malignant Pleural Effusion: Interleukin-15 vs. Interleukin-2. Journal of Interferon & Cytokine Research. 20(1). 31–39. 17 indexed citations

14.

Liu, Jacqueline Ming, Ming‐Fang Wu, Wei-Chun Lin, et al.. (1998). Ifosfamide-based chemotherapy for previously treated lung cancer patients.. PubMed. 61(7). 389–96. 1 indexed citations

15.

Wu, Ming‐Fang, R.-P. Perng, Wen‐chang Lin, et al.. (1997). Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer. Japanese Journal of Clinical Oncology. 27(2). 76–79. 3 indexed citations

16.

Tsai, C.-M., et al.. (1997). Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.. Journal of Clinical Oncology. 15(5). 2097–2102. 128 indexed citations

17.

Tsai, C.-M., et al.. (1996). Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.. PubMed. 56(4). 794–801. 34 indexed citations

18.

Tsai, C.-M., Karen Chang, Li‐Hwa Wu, et al.. (1996). Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Lung Cancer. 15(1). 152–152. 89 indexed citations

19.

Goldstein, Lori J., M M Gottesman, Ira Pastan, et al.. (1989). MDR1 Gene Expression in Lung Cancer. JNCI Journal of the National Cancer Institute. 81(15). 1144–1150. 164 indexed citations

20.

Tsai, C.-M., Adi F. Gazdar, David Venzon, et al.. (1989). Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).. PubMed. 49(9). 2390–7. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact